Back to Archived News
Celator Pharmaceuticals Issued U.S. Patent Related to CombiPlex® Technology Platform
Thursday, December 16, 2010
Princeton, NJ -- Celator Pharmaceuticals today announced the United States Patent and Trademark Office issued U.S Patent No. 7,850,990. This patent adds to the intellectual property surrounding Celator’s innovative technology platforms and products.
U.S. Patent No. 7,850,990 covers the CombiPlex® technology platform, the basis for Celator's two clinical-stage products. CombiPlex is a unique approach using drug carriers (nano-scale liposomes) to deliver synergistic ratios of drug combinations for the treatment of cancer. Celator's research identified that different ratios of the same drugs can be synergistic, additive, or antagonistic. In contrast to conventional combination drug regimens, which do not take this potential into account, CombiPlex identifies a synergistic ratio of the drugs and locks that combination in nano-scale (about 100 times smaller than a red blood cell) carriers that are able to deliver and maintain the synergistic drug ratio after injection into patients. This extended delivery of a synergistic ratio of drugs is intended to increase the effectiveness of the combination and improve clinical outcomes.
“We’re pleased to receive this patent which broadly protects Celator’s CombiPlex technology, the foundation of our current product pipeline,” said Scott Jackson, chief executive officer of Celator Pharmaceuticals. “Our lead investigational product, CPX-351, recently reported positive Phase 2 data and planning is underway for Phase 3. With the Patent Term Adjustment, this patent provides protection until January 2027, which significantly extends market exclusivity for CPX-351.”
About CPX-351
CPX-351 (Cytarabine:Daunorubicin) Liposome Injection represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. CPX-351 has been granted orphan drug status by the U.S. Food & Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML). CPX-351 is currently in phase 2 clinical development for the treatment of AML. Celator has completed a successful randomized, phase 2 study comparing CPX-351 to the standard "7+3" regimen of cytarabine:daunorubicin in patients 60-75 years of age with newly diagnosed AML and has completed enrollment in a randomized, phase 2 study of CPX-351 versus intensive salvage therapy in patients 18-65 years of age with AML in first relapse. The second study is supported by The Leukemia & Lymphoma Society.
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two Phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.
Back to Archived News
